Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Cristina Villarroel"'
Autor:
Dave Singh, Victor Balaguer, Carol Astbury, Ulrika Wählby-Hamrén, Eulalia Jimenez, Beatriz Seoane, Cristina Villarroel, Alejhandra Lei, Ajay Aggarwal, Ioannis Psallidas
Publikováno v:
Respiratory Research, Vol 21, Iss S1, Pp 1-11 (2020)
Abstract Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β2−agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of s
Externí odkaz:
https://doaj.org/article/93216040456b455fbf133449fada5043
Autor:
Eulalia Jimenez, Carol Astbury, Muna Albayaty, Ulrika Wählby-Hamrén, Beatriz Seoane, Cristina Villarroel, Helena Pujol, Maria Jesus Bermejo, Ajay Aggarwal, Ioannis Psallidas
Publikováno v:
Respiratory Research, Vol 21, Iss S1, Pp 1-9 (2020)
Abstract Background Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β2-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, pharmacodynamics,
Externí odkaz:
https://doaj.org/article/5eb0ee5d18dd4886a2482e4d36b7db73
Autor:
Lauran Pelaez, Diego Alberto Calderon, Byron Alfredo Fun Sang, Lisbet Cristina Villarroel, Franck Salazar, Paul Israel Cornejo, Israel Reyes, Patricio Zamora, Cristian Gustavo Giol, Maria Martina Grefa, Maria Fernanda Pozo, Jonny Lomas, Anne Valdez
Publikováno v:
Day 3 Thu, April 28, 2022.
One of the main challenges in production enhancement in mature fields is finding the optimum method to develop different reservoirs under the best exploitation strategy. Ecuador's Eden Yuturi is a mature field where nearly 15% of the field's producti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c453fad9d5038dd061dd5acfc14361e4
https://doi.org/10.2118/209308-ms
https://doi.org/10.2118/209308-ms
Autor:
Ulrika Wählby-Hamrén, Cristina Villarroel, Victor Balaguer, Alejhandra Lei, Beatriz Seoane, Dave Singh, Ajay Aggarwal, Eulalia Jimenez, Carol Astbury, Ioannis Psallidas
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss S1, Pp 1-11 (2020)
Respiratory Research, Vol 21, Iss S1, Pp 1-11 (2020)
Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β2−agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f1a1b8340ecb4882c35fefacbfaa7e
https://pubmed.ncbi.nlm.nih.gov/32907566
https://pubmed.ncbi.nlm.nih.gov/32907566
Autor:
Ajay Aggarwal, Cristina Villarroel, Alejhandra Lei, Beatriz Seoane, Carol Astbury, Dave Singh, Victor Balaguer, Lali Jimenez
Publikováno v:
Airway Pharmacology and Treatment.
AZD8871 is an inhaled long acting dual muscarinic antagonist/β 2 adrenoceptor agonist (MABA) under development for treatment of COPD and asthma. This 5-way complete crossover trial was designed to test efficacy, pharmacokinetics, safety and tolerabi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3ac9b56b43229e9151b8311ad185872
https://doi.org/10.1183/1393003.congress-2017.pa1798
https://doi.org/10.1183/1393003.congress-2017.pa1798
Autor:
Maria-Jesus Bermejo, Cristina Villarroel, Carol Astbury, Helena Pujol, Ajay Aggarwal, Beatriz Seoane, Lali Jimenez, Muna Albayaty
Publikováno v:
Airway Pharmacology and Treatment.
AZD8871 is an inhaled long acting dual muscarinic antagonist/ β 2 adrenoceptor agonist (MABA) under development for the treatment of COPD and asthma. This was an ascending-dose first in man trial, designed to test safety, tolerability, pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef1f1e2e9eddf15168071dc78379d2d7
https://doi.org/10.1183/1393003.congress-2017.pa1811
https://doi.org/10.1183/1393003.congress-2017.pa1811
Autor:
Mireia Junyent, Josep Brugada, Sònia Jiménez, Blanca Coll-Vinent, Ernest Bragulat, Òscar Miró, Lluís Mont, Miquel Sánchez, Marta Sitges, Josep Magriñà, Josefina Orús, Victor Obach, Gustavo Pacheco, Jordi Casademont, Cristina Villarroel
Publikováno v:
Medicina Clínica. 128:125-129
BACKGROUND AND OBJECTIVE: Atrial fibrillation is managed in multiple settings by different specialists. We sought to analyze treatment and compliance of the prevailing guidelines of patients with atrial fibrillation attended at different levels of he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::088b6758553b11cb10a05145e69f8d01
https://doi.org/10.1157/13098018
https://doi.org/10.1157/13098018
Autor:
Gui-Rong Guo, Shannon Flynn, Jie Li, Celin Tompkins, Margaret E. McLaughlin, Yan Wang, Chun Li, Anthony Boral, Peter G. Schultz, Jun Liu, Dai Cheng, Auzon Steffy, Colleen Kowal, Jianwei Che, Gary J. Vanasse, Jane Cheng, Nicholas Ng, H. Martin Seidel, Shifeng Pan, Shailaja Kasibhatla, M. Cristina Villarroel, J. Chad Brenner, Lilli Petruzzelli, Thomas E. Carey, Mindy H. Hsieh, Tao Wang, Martin P. Graham, Allen G. Li, Van Phung, Alwin Schuller, Fangxian Sun, William R. Sellers, Jennifer L. Harris, Anne Marie Pferdekamper, Peter McNamara, Xu Wu
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 110(50)
Wnt signaling is one of the key oncogenic pathways in multiple cancers, and targeting this pathway is an attractive therapeutic approach. However, therapeutic success has been limited because of the lack of therapeutic agents for targets in the Wnt p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ce2525c06404b700983441ad25af35
https://pubmed.ncbi.nlm.nih.gov/24277854
https://pubmed.ncbi.nlm.nih.gov/24277854
Autor:
Michelle A. Rudek, John Wright, Maria Cristina Villarroel, Keith W. Pratz, Linping Xu, B. Douglas Smith
Publikováno v:
Investigational new drugs. 30(6)
Sorafenib is an orally administered multikinase inhibitor that exhibits antiangiogenic and antitumor activity. Few investigators have been able to correlate cumulative sorafenib dose or total exposure to pharmacodynamic effects. This discrepancy may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21eda92451264e56c56564bc69a5f5a2
https://pubmed.ncbi.nlm.nih.gov/22089297
https://pubmed.ncbi.nlm.nih.gov/22089297
Autor:
Daniel A. Laheru, Anirban Maitra, Alison P. Klein, Ana De Jesus-Acosta, Ralph H. Hruban, Maria Cristina Villarroel, Manuel Hidalgo, N. V. Rajeshkumar, Siân Jones, Ross C. Donehower, James R. Eshleman, Ignacio Garrido-Laguna
Publikováno v:
Molecular cancer therapeutics. 10(1)
Metastasis and drug resistance are the major causes of mortality in patients with pancreatic cancer. Once developed, the progression of pancreatic cancer metastasis is virtually unstoppable with current therapies. Here, we report the remarkable clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83f5afde5a4df4b04382be51befbe34f
https://pubmed.ncbi.nlm.nih.gov/21135251
https://pubmed.ncbi.nlm.nih.gov/21135251